A combined detection model of markers for the diagnosis of lung cancer

Abstract

The invention discloses a marker combined detection model that can be used for lung cancer diagnosis. The present invention provides the application of carcinoembryonic antigen, cancer antigen 125, annexin A1 antibody and α-enolase antibody as markers in preparing a product for diagnosing or assisting diagnosis of lung cancer. The present invention establishes a good optimization model whose diagnostic ability is obviously superior to that of a single traditional marker - the best diagnostic combination of four biomarkers (CEA, CA125, Annexin A1 antibody and α-enolase antibody). As a new method for lung cancer diagnosis, the invention has high sensitivity and specificity, and is of great significance for accurate diagnosis of lung cancer.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a marker combined detection model that can be used for lung cancer diagnosis. Background technique [0002] Lung cancer is one of the most common malignant tumors in clinic, with high degree of malignancy and rapid course of disease development. According to the data released by the Ministry of Health, lung cancer has become the leading cause of death from malignant tumors in my country, accounting for more than 20% of all malignant tumors. [0003] Accurate diagnosis of lung cancer is the key to reducing mortality, but there is still a lack of effective diagnostic methods, and more than 70% of lung cancer patients have missed the best time for treatment when they are diagnosed. Currently, there are two main methods for diagnosing lung cancer: histology and imaging, but both methods have certain limitations. With the development of immunology and molecular biology, tumor-related protein...

Images